PRZEGLĄD PREPARATÓW NAJCZĘŚCIEJ STOSOWANYCH  W LECZENIU CHORÓB GRZYBICZYCH

Marta Szymańska; Andrzej Baranowski; Dariusz Płachta

doi:10.56782/pps.56

Published : 2007-03-28

Vol. 5 No. 1 (2007)

A REVIEW OF THE MOST OFTEN USED MEDICINES IN THE TREATMENT OF FUNGAL INFECTIONS

Marta Szymańska

Andrzej Baranowski

Dariusz Płachta

DOI: https://doi.org/10.56782/pps.56

Abstract

Effective treatment of fungal infections depends on a proper selection of the antifungal agents. A number of medicines have been recently introduced into antifungal therapy differing by the chemical structure and mechanism of action. Antifungal resistance, toxicity, drug interactions and expenses limit current treatment strategies. The search for novel, more effective and less toxic antifungal drugs is in progress.

Keywords:

antifungal drugs, fungal infections

Similar Articles

Kacper Jasiński, Paulina Oleksa, Daria Żuraw, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Bartosz Pawłowski, The effectiveness of the immune-boosting preparations in prevention and treatment of respiratory infections , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska, Drugs and other chemical substances inducing diabetes – review of the literature , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula, The glucagon-like peptide-1 analogues therapy in the non-diabetic patients , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
Bartłomiej Pyrak, Karolina Rogacka, Dariusz Maciej Pisklak, Anti-leukotriene drugs in the therapy of inflammatory diseases , Prospects in Pharmaceutical Sciences: Vol. 20 No. 2 (2022)
Paulina Brewczyńska, Justyna Makowska, Dorota Skrajnowska, Marta Teryks, Andrzej Tokarz, ADDICTION TO CONVENTIONAL AND ELECTRONIC CIGARETTES AND THE RISKS OF PHARMACOTHERAPY IN SMOKERS. , Prospects in Pharmaceutical Sciences: Vol. 13 No. 3 (2015)
Angelika Lis, Katarzyna Wyszomierska, Katarzyna Znajdek, Łukasz Szeleszczuk, Monika Zielińska-Pisklak, PHOTOSENSITIVITY PHENOMENON – A SIGNIFICANT ADVERSE EFFECT OF COMMONLY USED DRUGS , Prospects in Pharmaceutical Sciences: Vol. 19 No. 3 (2021)
Piotr Bojanowski, Piotr F. J. Lipiński, Paweł Czekała, Dariusz Plewczyński, MULTITARGET DRUGS – A NEW PARADIGM IN DRUG DESIGN , Prospects in Pharmaceutical Sciences: Vol. 11 No. 1 (2013)
Joanna Warguła, Outline of the history of drug synthesis with particular emphasis on anticancer and antibacterial drugs , Prospects in Pharmaceutical Sciences: Vol. 20 No. 3 (2022)
Anna Dominiczak, Agata Janczak, Martyna Wołek, Katarzyna Mazurek, Maciej Bara, Proton pump inhibitors: prolonged intake and adverse effects , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Jadwiga Turło, FUNGAL BIOTECHNOLOGY. APPLICATIONS IN PHARMACY AND SUPPLEMENTATION , Prospects in Pharmaceutical Sciences: Vol. 11 No. 3 (2013)

1 2 3 4 5 6 7 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Szymańska, M., Baranowski, A., & Płachta, D. (2007). A REVIEW OF THE MOST OFTEN USED MEDICINES IN THE TREATMENT OF FUNGAL INFECTIONS. Prospects in Pharmaceutical Sciences, 5(1), 1–12. https://doi.org/10.56782/pps.56

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Chmielewska L., Krasowska A.: Antybiotyki nie zawsze nasi sprzymierzeńcy. "Aura. Ochrona środowiska"- miesięcznik popularnonaukowy Naczelnej Organizacji Technicznej, Wydawnictwo Czasopism i Książek Technicznych SIGMA-NOT Sp. z o.o. 2001, sierpień, Warszawa.

Janiec W., Krupińska J.: Farmakodynamika. Podręcznik dla studentów farmacji. Wydawnictwo Lekarskie PZWL, Wydanie V unowocześnione. 2002;1004-1008.

Nowicki R.: Farmakoterapia grzybic powierzchniowych: http://www.vita.csc.pl/farmakoterapia.php.

Kaczmarek J., Bocheńska-Marciniak M.: Grzyby i ich udział w chorobach alergicznych. Terapia Alergologia. 2002;119:47-53.

Braham C., Ezzine Sebai N., Arrese J.E., et al.: Il y a sports et spores. Le pied, ses mycoses et onychomycoses. Rev. Med. Liege. 2001;56(11):773-776.

Lacroix C., Baspeyras M., de La Salmoniere P., et al.: Tinea pedis in European marathon runners. JEADV. 2002;16:139-142. DOI: https://doi.org/10.1046/j.1468-3083.2002.00400.x

Hay R.J., Robles W., Midgley G., et al.: Tinea capitis in Europe: new perspective on an old problem. JEADV. 2001;15:229-233. DOI: https://doi.org/10.1046/j.1468-3083.2001.00214.x

Rinaldi M.G.: Dermatophytosis: epidemiological and microbiological update. J. Am. Acad. Dermatol. 2000;43(5):120-124. DOI: https://doi.org/10.1067/mjd.2000.110378

Scheynius A., Johansson C., Buentke E., et al.: Atopic Eczema/Dermatitis Syndrome and Malassezia Int. Arch. Allergy Immunol. 2002;127(3):161-169. DOI: https://doi.org/10.1159/000053860

Lindborg M., Magnusson C.G.M., Zargari A., et al.: Selective cloning of allergens from the skin colonizing yeast Malassezia furfur by phage surface display technology. J. Invest. Dermatol. 1999;113:156-161. DOI: https://doi.org/10.1046/j.1523-1747.1999.00661.x

Korting H.C., Schaller M.: Neue Entwicklungen in der medizinischen Mykologie. Hautarzt. 2001;52:91-97. DOI: https://doi.org/10.1007/s001050051271

Adamski Z., Deja M.: Nowości i przyszłość w terapii przeciwgrzybiczej. Mikol. Lek. 2005;12(2):115-121.

Aoki Y., Yamamoto M., Hosseini-Mazinani S.M., Koshikawa, N. Sugimoto K., Arisawa M.: Antimicrob. Agents Chemother. 1996;40:127-132. DOI: https://doi.org/10.1128/AAC.40.1.127

Pfaller M.A., et al.: Comparison of visual and spectrophotometric methods for MIC endpoint determinations by using broth microdilution methods to test five antifungal agents including the new triazole DoSyo: Clin. Mikrobiol. 1995;533:1094-1097. DOI: https://doi.org/10.1128/jcm.33.5.1094-1097.1995

Pfaller M.A., et al.: International surveillance of bloodstream infections due to Candida species in the European SENTRY programe: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbol. Infect. Dis. 1999;35:19-25. DOI: https://doi.org/10.1016/S0732-8893(99)00046-2

Marco F., et al.: Activity of Mk-0991 (L-743,872) a new echinocandin compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida sp. Diagn. Microbiol. Infect. Dis. 1998;32:33-37. DOI: https://doi.org/10.1016/S0732-8893(98)00050-9

Didomenico B.: Novel antifungal drugs. Curr. Opin. Microb. 1999;2:509-515. DOI: https://doi.org/10.1016/S1369-5274(99)00009-0

Hryncewicz-Gwóźdź A., Plomer-Niezgoda E., Baran W.: Perspektywy terapii przeciwgrzybiczej. Mikol. Lek. 2003;10:207-211.

DeWet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., Diekmann-Berndt H.: A randomized, double-blind, parallel - group, dose-response study of micafungin compared with fluconazole for treatment of esophagea candidiasis in HIV-positive patients. Clin. Infect. Dis. 2004;15:842-849. DOI: https://doi.org/10.1086/423377

Polak A.: Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy. 1978;24(1):2-16. DOI: https://doi.org/10.1159/000237753

Vermes A., et al.: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000;46:171-9. DOI: https://doi.org/10.1093/jac/46.2.171

Zejc A., Gorczyca M.: Chemia leków. Wydawnictwo Lekarskie PZWL, Wydanie II zmienione. 2002;700-703.

Gupta A.K., Skinner A.R.: Ciclopirox for the treatment of superficial fungal infections: a review. Int. J. Dermatol. 2003;42(1):3-9. DOI: https://doi.org/10.1046/j.1365-4362.42.s1.2.x

Lee J.H., Lee H.S., Eun H.C., et al: Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. J. Dermatol. Treat. 2003;14:212-215. DOI: https://doi.org/10.1080/714070652

Sterling T.R., Gasser R.A. Jr , Ziegler A.: Emergence of resistance to amphotericin B during therapy for candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. 1996;23:187-188. DOI: https://doi.org/10.1093/clinids/23.1.187

Walsh T.J., Finberg R.W., Arndt C., et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999;340:764-771. DOI: https://doi.org/10.1056/NEJM199903113401004

Prajna N.V., Nirmalan P.K., Mahalakshmi R., Lalitha P., Srinivasan M.: Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis. Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India. Cornea. 2004; 23(8):793-6. DOI: https://doi.org/10.1097/01.ico.0000134193.64357.82

Millns B., Martin M.V.: Nystatin pastilles and suspension in the treatment of oral candidosis. Br. Dent. J. 1996;181:209-11. DOI: https://doi.org/10.1038/sj.bdj.4809214

Gøtzsche P.C., Johansen H.K.: Nystatin prophylaxis and treatment in severely immunodepressed patients. Available in The Cochrane Library; Issue 2. Chichester: Wiley J.: 2004.

Komori T.: Trichomycin B, a polyene macrolide from Streptomyces. Research and Technology Group, Fujisawa Pharmaceutical Co., Ltd., Japan. J. Antibiot. 1990;43(7): 778-82. DOI: https://doi.org/10.7164/antibiotics.43.778

Norgaard O.: Pecilocin allergy. Hautarzt. 1977;28(1):35-6.

O'Sullivan D.P.: Terbinafine: tolerability in general medical practice. Br. J. Dermatol. 1999;141(56):21-5. DOI: https://doi.org/10.1046/j.1365-2133.1999.00010.x

Fuller L.C., et al.: A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br. J. Dermatol. 2001;144:321-7. DOI: https://doi.org/10.1046/j.1365-2133.2001.04022.x

Ablon G., Rosen T., Spedale J.: Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Department of Dermatology, Baylor College of Medicine, USA. Int. J. Dermatol. 1996;35(8):591-3. DOI: https://doi.org/10.1111/j.1365-4362.1996.tb03668.x

Haria M., Bryson H.M.: Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49:103-20. DOI: https://doi.org/10.2165/00003495-199549010-00008

Alchorne M.M., Paschoalick R.C., Forjaz M.H.: Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin. Ther. 1987;9:360-367.

Jones R.N., Bale M.J., Hoban D., et al: In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (Vagistat-1 6.5%) application. Diagn. Microbiol. Infect. Dis. 1993;17:45-51. DOI: https://doi.org/10.1016/0732-8893(93)90069-J

Carrillo-Munoz A.J., Tur-Tur C., Bornay-Llinares F.J., et al: Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 1999;11(3):187-190.

Dellenbach P., Thomas J.L., Guerin V., et al: Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int. J. Gynecol. Obstet. 2000;71:47-52. DOI: https://doi.org/10.1016/S0020-7292(00)00348-9

Prajna N.V., John R.K., Nirmalan P.K., et al: A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br. J. Ophthalmol. 2003: 87:1235-1237.

Van Esso D., Fajo G., Losada I., et al: Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clin. Ther. 1995;17:264-269. DOI: https://doi.org/10.1016/0149-2918(95)80024-7

Prajna N.V., John R.K., Nirmalan P.K., et al.: A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br. J. Ophthalmol. 2003;87:1235-1237. DOI: https://doi.org/10.1136/bjo.87.10.1235

Fontana C., Cammarata E., Greco M., et al: In vitro activity of fenticonazole on trichomonas vaginalis and gardnerella vaginalis. Curr. Ther. Res. 1990; 48:44-51.

Fioroni A., Terragni L., Vannini P., et al: Fenticonazole plasma levels during treatment with fenticonazole 2% cream and spray in patients with dermatomycoses. Curr. Ther. Res. 1990;47:997-1003.

Gugnani H.C., Akpata L.E., Gugnani M.K., et al: Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses. 1994;37(1-2):39-41. DOI: https://doi.org/10.1111/j.1439-0507.1994.tb00283.x

Lazarov A., Ingber A.: Pustular allergic contact dermatitis to isoconazole nitrate. Am. J. Contact. Derm. 1997;8(4):229-230. DOI: https://doi.org/10.1097/01206501-199712000-00008

Stevens R.E., Konsil J., Verrill S.S., et al: Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J. Clin. Pharmacol. 2002;42:52-60. DOI: https://doi.org/10.1177/0091270002042001006

Fernandez L., Maquiera E., Rodriguez F., et al: Systemic contact dermatitis from miconazole. Contact Dermatitis. 1996;34:217. DOI: https://doi.org/10.1111/j.1600-0536.1996.tb02178.x

Tsunoda S.M., Velez R.L., von Moltke L.L., et al: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 1999;66:461-471. DOI: https://doi.org/10.1016/S0009-9236(99)70009-3

Cuce L.C.: Sulconazole nitrate 1% cream vs clotrimazole 1% cream in the treatment of tinea pedis. Curr. Ther. Res. 1989;45:421-427.

Hajman A.J.: Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream. J. Int. Med. Res. 1988;16:367-375. DOI: https://doi.org/10.1177/030006058801600506

Brown D., Henzl M.R., Kaufman R.H. and the Gynazole 1 Study Group.: Butoconazole nitrate 2% for vulvovaginal candidiasis; new, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. J. Reprod. Med. 1999;44:933-938.

Kohl T.D., Martin D.C., Berger M.S.: Comparison of topical and oral treatments for tinea gladiatorum. Clin. J. Sport. Med. 1999; 9(3):161-166. DOI: https://doi.org/10.1097/00042752-199907000-00008

Mselle J.: Use of topical clotrimazole in human keratomycosis. Ophthalmologica. 2001; 215:357-360. DOI: https://doi.org/10.1159/000050885

Woolley P.D., Higgins S.P.: Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. Brit. J. Clin. Pract. 1995;49:65-66.

Plomer-Niezgoda E., Baran E.: Flutrimazol - ocena właściwości farmakologicznych i klinicznych. Mikol. Lek. 2002;9(1):41-44.

Bartroli J., Alquero M., Boncompte E., Forn J.: Synthesis and antifungal activity of series of difluorotritylimizoles. Arzneim.-Forsch./Drug Res. 1992;42:832-855.

Beierdoerffer H: Erfahrungen mit Croconazol in der dermatologischen Praxis. Der Deutsche Dermatologe. 1993;12:1.

Meinicke K., Michel G.: Croconazole: a new broad-spectrum agent in the treatment of fungal skin infections. Int. J. Clin. Pharmacol. Res. 1994;14:139-148.

Amichai B.: Treatment of pityriasis versicolor with a shampoo containing 1% bifonazole (Agispor® shampoo) in children. Clin. Exp. Dermatol. 2000;26:655-660. DOI: https://doi.org/10.1046/j.1365-2230.2000.00730-6.x

Carrillo-Munoz A.J., Tur-Tur C., Bornay-Llinares F.J., et al.: Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 1999;11(3):187-190. DOI: https://doi.org/10.1179/joc.1999.11.3.187

Gugnani H.C., Ideyi C., Gugnani M.K.: Oxiconazole in the treatment of tropical dermatomycoses. Curr. Ther. Res. 1993;54:122-125. DOI: https://doi.org/10.1016/S0011-393X(05)80625-3

Pariser D.M., Pariser R.J.: Oxiconazole nitrate lotion, 1 percent: an effective treatment for tinea pedis. Cutis. 1994;54:43-44.

Bulkowstein M., Mordish Y., Zimmerman D.R. et al: Ketoconazole-induced neurologic sequelae. Vet. Hum. Toxicol. 2003;45(5):239-240.

Millikan R., Baez L., Banergee T., et al.: Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urologic Oncology. 2001;6:111-115. DOI: https://doi.org/10.1016/S1078-1439(00)00123-X

Moody D.E., Walsh S.L., Rollins D.E., et al: Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin. Pharmacol. Ther. 2004;76(2):154-166. DOI: https://doi.org/10.1016/j.clpt.2004.04.004

Unholzer A., Schinzel S., Nietsch K.H., et al: Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis. A double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin. Drug. Invest. 2002;22(3):167-172. DOI: https://doi.org/10.2165/00044011-200222030-00003

Muijsers R.B.R., et al.: Voriconazole: in the treatment of invasive aspergillosis. Drugs. 2002;62:2655-64. DOI: https://doi.org/10.2165/00003495-200262180-00010

Pearson M.M., et al.: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 2003;37:420-32. DOI: https://doi.org/10.1345/aph.1C261

Pappas P.G., et al.: Alopecia associated with fluconazole therapy. Ann. Intern. Med. 1995; 123:354-7. DOI: https://doi.org/10.7326/0003-4819-123-5-199509010-00006

Bronstein J.A., et al.: Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin. Infect. Dis. 1997;25:1266-7. DOI: https://doi.org/10.1086/516975

Takahashi T., et al.: Desensitization to fluconazole in an AIDS patient. Ann. Pharmacother. 2001;35:642-3. DOI: https://doi.org/10.1345/aph.10285

Fung-Tomc J.C., Huczko E., Minassian B., Bonner D.P.: In vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 1998;42:313-318. DOI: https://doi.org/10.1128/AAC.42.2.313

Sheehan D.J., Hitchcock C.A., Sibley C.M.: Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999;12:40-79. DOI: https://doi.org/10.1128/CMR.12.1.40

Meletiadis J., et al.: In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 2000;44:470-2. DOI: https://doi.org/10.1128/AAC.44.2.470-472.2000

Goldman M., et al.: Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob. Agents Chemother. 2000;44:1585-7. DOI: https://doi.org/10.1128/AAC.44.6.1585-1587.2000

Dannaoui E., et al.: Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 2001;47:333-340. DOI: https://doi.org/10.1093/jac/47.3.333

Garcia F.R.G., Sauceda L., Ramirez P.D., Cruz T.F., Romero C.R.: Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis. Ginecol. Obstet. Mex. 2000;68:154-9.

Courtney R., Pai S., Laughlin M., et al.: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 2003;47:2788-2795. DOI: https://doi.org/10.1128/AAC.47.9.2788-2795.2003

Courtney R., Radwanski E., Lim J., et al: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 2004;48:804-808. DOI: https://doi.org/10.1128/AAC.48.3.804-808.2004

Herbrecht R.: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 2004;58(6):612-624. DOI: https://doi.org/10.1111/j.1368-5031.2004.00167.x

Segal B.H. et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. 2005;40:1684-8. DOI: https://doi.org/10.1086/430068

Carrillo-Munoz A.J., Quindos G., Lopez-Ribot J.L.: Current Developments in Anti-Fungal Agents. Current Medicinal Chemistry - Anti-Infective Agents. 2004;3(27):297-323. DOI: https://doi.org/10.2174/1568012043353766

Sorbera, L.A., Bartroli, J., Castaner, J.: In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 2004;48(2):384-7. DOI: https://doi.org/10.1128/AAC.48.2.384-387.2004

Benfield P. Clissold S.P.: Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1988;35:143-153. DOI: https://doi.org/10.2165/00003495-198835020-00004

Marta Szymańska

Affiliation:

Katedra i Zakład Chemii Organicznej Wydział Farmaceutyczny Akademii Medycznej w Warszawie Poland

Andrzej Baranowski

Affiliation:

Katedra i Zakład Chemii Organicznej Wydział Farmaceutyczny Akademii Medycznej w Warszawie Poland

Dariusz Płachta

Affiliation:

Katedra i Zakład Chemii Organicznej Wydział Farmaceutyczny Akademii Medycznej w Warszawie Poland